Abstract
Due to the intimate relationship between liver and kidney disease in hepatitis C virus (HCV) infection, treatment options for HCV-positive patients at any stage of chronic kidney disease (CKD) are essential. The availability of second-generation, direct-acting antiviral (DAA) combinations has allowed for the advent of interferon-sparing treatment regimens with shorter durations and minimal side effects. While many of the second-generation DAAs are principally metabolized by the hepatic system, dosing in severe renal impairment (creatinine clearance [CrCl] <30 mL/min) or dialysis has remained questionable due to limited experience. New evidence regarding the use of these agents in renal impairment continues to become available, as real-world experience with these treatment regimens is reported. Simeprevir, ledipasvir, paritaprevir, ombitasvir, dasabuvir, and daclatasvir have data to suggest safety in end-stage renal disease. While safety and efficacy with sofosbuvir remains uncertain, data are now available to support utilizing a dose adjustment when glomerular filtration rates are <30 mL/min. Upcoming regimens grazoprevir/elbasvir and daclatasvir/asunaprevir/beclavubir may provide further options for patients with advanced kidn...Continue Reading
References
Sep 1, 1980·The Journal of Clinical Investigation·J Roth
Dec 1, 1993·Kidney International·M JadoulC van Ypersele de Strihou
Jul 1, 1993·Journal of Clinical Microbiology·C S HuangC A Tan
Apr 1, 1997·Kidney International·B J Pereira, A S Levey
Feb 12, 2000·Medicine·P CacoubJ C Piette
Aug 27, 2005·The Lancet Infectious Diseases·Colin W ShepardMiriam J Alter
Jun 7, 2007·World Journal of Gastroenterology : WJG·Miriam J Alter
Jun 27, 2007·Archives of Internal Medicine·Judith I TsuiAnn M O'Hare
Mar 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for the Study of Liver Diseases
Sep 8, 2009·The American Journal of Cardiology·Chetan V HampoleSanjiv J Shah
Jan 1, 2009·Journal of Global Infectious Diseases·Luis Jesuino de Oliveria AndradeRaymundo Paraná
Nov 22, 2013·Kidney International·Yi-Chun ChenYu-Chieh Su
Dec 7, 2013·Journal of Viral Hepatitis·W-C LiS-S Loke
Jun 28, 2014·PloS One·Jia-Jung LeeShang-Jyh Hwang
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Mark S SulkowskiUNKNOWN PHOTON-1 Investigators
Feb 6, 2015·Antiviral Therapy·Tushar GarimellaMarc Bifano
Mar 3, 2015·World Journal of Hepatology·Chalermrat BunchorntavakulDisaya Chavalitdhamrong
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver
May 13, 2015·JAMA : the Journal of the American Medical Association
Citations
Sep 28, 2017·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lamis R KaraouiElias B Chahine
Sep 9, 2016·World Journal of Gastroenterology : WJG·Juliana Cristina Santiago BastosClarice Weis Arns
Oct 16, 2019·International Urology and Nephrology·Ahmed Yahia ElmowafyMohamed Adel Bakr
Jul 18, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marcello PersicoMario Masarone
Feb 11, 2020·JHEP Reports : Innovation in Hepatology·Elizabeth C VernaRobert S Brown
Jan 12, 2021·Expert Review of Anti-infective Therapy·Szu-Jen WangMing-Lung Yu